about our pipeline news october 12 2016gtx announces 14.0 million registered direct common stock offering more september 8 2016gtx achieves stage 1 milestone in phase 2 clinical trial of enobosarm in er ar breast cancer more information request contact careers search search about overview management team board of directors careers contact pipeline overview breast cancer stress urinary incontinence duchenne muscular dystrophy prostate cancer diseases overview breast cancer stress urinary incontinence duchenne muscular dystrophy prostate cancer science overview selective androgen receptor modulator sarm the potential advantage of sarms sarms in breast cancer sarms in muscle diseases sarms in urology selective androgen receptor degrader sard investors overview news releases events & presentations financial reports sec filings stock information historic stock lookup investment calculator analyst coverage corporate governance management board of directors committee composition investor faqs contact us developing hormone receptor based medicines for lif 2016 gtx inc. all rights reserved terms & conditions menu about overview management team board of directors careers contact pipeline overview breast cancer stress urinary incontinence duchenne muscular dystrophy prostate cancer diseases overview breast cancer stress urinary incontinence duchenne muscular dystrophy prostate cancer science overview selective androgen receptor modulator sarm the potential advantage of sarms sarms in breast cancer sarms in muscle diseases sarms in urology selective androgen receptor degrader sard investors overview news releases events & presentations financial reports sec filings stock information historic stock lookup investment calculator analyst coverage corporate governance management board of directors committee composition investor faqs contact us